Menu
Search
|

Menu

Close
X

Dynavax Technologies Corp DVAX.OQ (NASDAQ Stock Exchange Capital Market)

15.95 USD
-- (--)
As of Jun 22
chart
Previous Close 15.95
Open --
Volume --
3m Avg Volume 341,215
Today’s High --
Today’s Low --
52 Week High 24.45
52 Week Low 8.15
Shares Outstanding (mil) 59.75
Market Capitalization (mil) 1,380.17
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.83 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
11
FY15
4
EPS (USD)
FY18
-0.631
FY17
-1.846
FY16
-2.920
FY15
-3.108
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.74
Price to Sales (TTM)
vs sector
179.08
5.71
Price to Book (MRQ)
vs sector
9.00
5.37
Price to Cash Flow (TTM)
vs sector
--
23.32
Total Debt to Equity (MRQ)
vs sector
0.00
16.46
LT Debt to Equity (MRQ)
vs sector
0.00
12.19
Return on Investment (TTM)
vs sector
-72.82
14.38
Return on Equity (TTM)
vs sector
-73.07
16.08

EXECUTIVE LEADERSHIP

Arnold Oronsky
Independent Chairman of the Board, Since 2006
Salary: --
Bonus: --
Eddie Gray
Chief Executive Officer, Director, Since 2013
Salary: $600,000.00
Bonus: --
Michael Ostrach
Chief Financial Officer, Senior Vice President, Chief Business Officer, Since 2016
Salary: $425,000.00
Bonus: --
Robert Coffman
Senior Vice President, Chief Scientific Officer, Since 2014
Salary: $466,796.00
Bonus: --
Robert Janssen
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs, Since 2018
Salary: $400,000.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

2929 7th St Ste 100
BERKELEY   CA   94710-2753

Phone: +1510.8485100

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its products include HEPLISAV-B, AZD1419, SD-101, DV281, DV230F and DV1001. HEPLISAV-B is an investigational adult hepatitis B vaccine. AZD1419 is being developed for the treatment of asthma. SD-101 is an investigational TLR9 agonist designed to elicit a potent and focused immune response to cancer. DV281 is an investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV230F is indicated for the treatment of Liver Tumors. DV1001 targets TLR 7 and 8 agonist for multiple malignancies. DV230F and DV1001 are in pre-clinical stage of development.

SPONSORED STORIES